NDA 207981 · Taiho Oncology
Lonsurf
Tipiracil Hydrochloride, Trifluridine · Oral · Nucleoside Analog Antiviral; Nucleoside Metabolic Inhibitor
NovelOrphanLast checked: Nov 20, 2026Latest source record: Aug 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Sep 22, 2015
Approved uses
3
Original approval plus efficacy supplements
Registered trials
185
32 Phase 3, 43 recruiting
FAERS reports
10,823
8,549 serious, 4,240 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 5, 2025.
LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. ( 1.2 ) 1.1 Metastatic Colorectal Cancer LONSURF, as a single agent or in combination with bevacizumab, is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. 1.2 Metastatic Gastric Cancer LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
Mechanism: LONSURF consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil, at a molar ratio 1:0.5 (weight ratio, 1:0.471). Inclusion of tipiracil increases trifluridine exposure by inhibiting its metabolism by thymidine phosphorylase. Following uptake into cancer cells, trifluridine is incorporated into DNA, interferes with DNA synthesis and inhibits cell proliferation. Trifluridine/tipiracil demonstrated anti-tumor activity against KRAS wild-type and mutant human colorectal cancer xenografts in mice.
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 2, 2023 Supplement 12 · Efficacy · priority review OrphanLabelLetterReview
- Feb 22, 2019 Supplement 8 · Efficacy · priority review OrphanLabelLetter
- Sep 22, 2015 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination NovelOrphanLabelReviewSummary Review
2 products under this application
- LONSURF · TIPIRACIL HYDROCHLORIDE EQ 6.14MG BASE; TRIFLURIDINE 15MG · TABLET, ORAL · Prescription · TE AB
- LONSURF · TIPIRACIL HYDROCHLORIDE EQ 8.19MG BASE; TRIFLURIDINE 20MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Tipiracil" as an intervention, any sponsor and status, largest first.
- Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal CancerPivotal-lookingRecruiting
Centre Hospitalier Universitaire DijonAcademic, hospital or other
NCT06197425 · 1,660 participants (planned) · Start May 7, 2026 · Primary completion May 2032
Drug: "FOLFIRI" cures; Trifluridine cures and 1 more · For: Colon or Upper Rectum Adenocarcinoma
Sites: Dijon, France
- A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)Pivotal-lookingRecruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT07549412 · 1,020 participants (planned) · Start May 6, 2026 · Primary completion Oct 16, 2029
Drug: Precemtabart tocentecan; Bevacizumab and 1 more · For: Metastatic Colorectal Cancer
Sites: San Francisco, California; Lone Tree, Colorado; Fort Myers, Florida · 116 sites in all
AbbVieAbbVie (ABBV)
NCT07525206 · 990 participants (planned) · Start May 22, 2026 · Primary completion May 2029
Drug: Telisotuzumab adizutecan; Bevacizumab and 1 more · For: Colorectal Cancer
Sites: Goodyear, Arizona; Springdale, Arkansas; Duarte, California · 91 sites in all
- AB122 Platform StudyRecruiting
Taiho Pharmaceutical Co., Ltd.Industry
NCT04999761 · 917 participants (planned) · Start Jun 1, 2021 · Primary completion Jun 2027
Drug: AB122; AB122 and 19 more · For: Advanced or Metastatic Solid Tumor; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer and 6 more
Sites: Aichi, Japan; Chiba, Japan; Ehime, Japan · 9 sites in all
- A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).Pivotal-lookingCompleted
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT03306394 · 907 participants · Start Oct 18, 2016 · Primary completion Nov 30, 2020
Drug: Trifluridine/Tipiracil hydrochloride (S95005) · For: Metastatic Colorectal Cancer
Sites: Camperdown, Australia; Darlinghurst, Australia; Fitzroy, Australia · 99 sites in all
- Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.Pivotal-lookingActive, not recruiting
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT03869892 · 856 participants · Start Mar 21, 2019 · Primary completion Jun 29, 2021
Drug: Trifluridine/tipiracil hydrochloride (S95005); Capecitabine and 2 more · For: Metastatic Colorectal Cancer
Sites: Berazategui, Argentina; Buenos Aires, Argentina; La Rioja, Argentina · 190 sites in all
- Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard ChemotherapiesPivotal-lookingCompleted
Taiho Oncology, Inc.Industry
NCT01607957 · 800 participants · Start Jun 17, 2012 · Primary completion Jan 31, 2014
Drug: TAS-102; Placebo · For: Colorectal Cancer
Sites: Glendale, Arizona; Fresno, California; Gilroy, California · 115 sites in all
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT05719558 · 798 participants (planned) · Start Mar 13, 2023 · Primary completion Apr 30, 2030
Drug: ASP1002; Bevacizumab and 10 more · For: Advanced Solid Tumors
Sites: New Haven, Connecticut; Plainville, Connecticut; Gainesville, Florida · 15 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death3,101
- disease progression1,795
- fatigue1,435
- nausea1,202
- diarrhoea1,040
- decreased appetite695
- vomiting649
- asthenia510
- white blood cell count decreased500
- anaemia375
- drug ineffective370
- neutropenia362
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 57 |
| 2016 | 1,355 |
| 2017 | 1,424 |
| 2018 | 1,345 |
| 2019 | 944 |
| 2020 | 964 |
| 2021 | 971 |
| 2022 | 870 |
| 2023 | 1,042 |
| 2024 | 752 |
| 2025 | 639 |
| 2026 | 460 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lonsurf (Trifluridine/Tipiracil HCl)
2024 spending
$226M
Beneficiaries
3,946
18,692 claims
Per beneficiary
$57,252
$245.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $107,441,017 |
| 2021 | $117,240,905 |
| 2022 | $142,418,647 |
| 2023 | $176,155,837 |
| 2024 | $225,915,435 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
Prager GW, Taieb J, Fakih M, et al. · N Engl J Med 2023 · Randomized Controlled Trial
- Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.
Fakih MG, Salvatore L, Esaki T, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Multicenter Study
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A, Lonardi S, Garcia-Carbonero R, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Multicenter Study
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Shitara K, Doi T, Dvorkin M, et al. · Lancet Oncol 2018 · Clinical Trial, Phase III, Multicenter Study
- Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.
Pietrantonio F, Salvatore L, Esaki T, et al. · J Clin Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Taiho Oncology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.